Ajinomoto North America has acquired US-based Cambrooke Therapeutics (Cambrooke) from Galen Partners and Seventure Partners for an undisclosed sum.

Cambrooke is engaged in the production of medical and specialised functional foods for people with chronic health conditions.

The acquisition will enable Cambrooke to gain access to Ajinomoto’s global nutrition and ingredient sciences expertise to focus on specialty nutrition.

The company can use Ajinomoto’s technologies on metabolic and ketogenic therapy products, as well as accelerated development of better nutritional solutions for more chronic conditions.

Cambrooke president and chief executive officer Howard Lossing said: “Ajinomoto’s corporate motto of ‘Eat Well, Live Well’ is an elegant statement that directly reflects Cambrooke’s mission of improving lives via providing the most delicious and most nutritious medical foods for people with chronic health conditions.

“In joining the Ajinomoto Group, our mission remains unchanged, our team remains in place, and our ability to better meet the needs of our customers expands with access to the enormous R&D capabilities of Ajinomoto.”

“The team at Cambrooke has been very successful in growing faster than other companies by better meeting the nutritional needs of the customers they serve.”

The deal will also allow Cambrooke to access flavour and texture-enhancing research and development capabilities of Ajinomoto.

Ajinomoto North America president Tatsuya Sato said: “Ajinomoto is deeply dedicated to improving lives through high-quality, good-tasting nutrition.

“We looked at many companies in recent years to help us grow in medical nutrition.

“The team at Cambrooke has been very successful in growing faster than other companies by better meeting the nutritional needs of the customers they serve.

“This success reflects a shared core value and led to our strong interest in Cambrooke joining the Ajinomoto Group.”